1. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins.
- Author
-
Altman T, Ionescu A, Ibraheem A, Priesmann D, Gradus-Pery T, Farberov L, Alexandra G, Shelestovich N, Dafinca R, Shomron N, Rage F, Talbot K, Ward ME, Dori A, Krüger M, and Perlson E
- Subjects
- Amyotrophic Lateral Sclerosis drug therapy, Animals, C9orf72 Protein genetics, DNA Helicases, DNA-Binding Proteins genetics, DNA-Binding Proteins pharmacology, Disease Models, Animal, Female, Humans, Induced Pluripotent Stem Cells, Mice, Mice, Inbred C57BL, Mitochondria drug effects, Mitochondrial Proteins chemistry, Mitochondrial Proteins genetics, Motor Neurons, Neurodegenerative Diseases drug therapy, Neuromuscular Junction drug effects, Neurons drug effects, Neurons metabolism, Neurons, Efferent, Phosphorylation, Poly-ADP-Ribose Binding Proteins, RNA Helicases, RNA Recognition Motif Proteins, Axons metabolism, DNA-Binding Proteins chemistry, DNA-Binding Proteins metabolism, Inhibition, Psychological, Mitochondrial Proteins metabolism, Neuromuscular Junction metabolism
- Abstract
Mislocalization of the predominantly nuclear RNA/DNA binding protein, TDP-43, occurs in motor neurons of ~95% of amyotrophic lateral sclerosis (ALS) patients, but the contribution of axonal TDP-43 to this neurodegenerative disease is unclear. Here, we show TDP-43 accumulation in intra-muscular nerves from ALS patients and in axons of human iPSC-derived motor neurons of ALS patient, as well as in motor neurons and neuromuscular junctions (NMJs) of a TDP-43 mislocalization mouse model. In axons, TDP-43 is hyper-phosphorylated and promotes G3BP1-positive ribonucleoprotein (RNP) condensate assembly, consequently inhibiting local protein synthesis in distal axons and NMJs. Specifically, the axonal and synaptic levels of nuclear-encoded mitochondrial proteins are reduced. Clearance of axonal TDP-43 or dissociation of G3BP1 condensates restored local translation and resolved TDP-43-derived toxicity in both axons and NMJs. These findings support an axonal gain of function of TDP-43 in ALS, which can be targeted for therapeutic development., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF